Nov 3 (Reuters) – Moderna Inc (MRNA.O) on Thursday cut its 2022 COVID-19 vaccine sales forecast, citing regulatory and production delays, and issued a 2023 outlook for the shots well below Wall Street estimates, sending its shares down as much like 9%.
It expects $4.5 billion to $5.5 billion in sales from signed COVID vaccine contracts for next year, while analysts’ estimates were at $9.5 billion.
That forecast comes despite the company delaying up to $3 billion worth of 2022 vaccine sales it would now deliver in 2023 due to quality control issues at its contract manufacturing partner. The company did say the 2023 outlook excludes expected contracts with countries such as the United States and Japan, and that it anticipated the forecast to be the “floor” for next year’s sales.
Demand for COVID vaccines has waned globally. Moderna agreed earlier this year to push back deliveries on its contract with the European Union to late 2022 or early 2023. It also canceled an existing deal with vaccine alliance GAVI, and struck a new deal to instead supply the organization up to 100 million doses. of its updated booster vaccine in 2023 for some of the world’s poorest countries.
Moderna’s new sales forecast comes after Pfizer Inc (PFE.N) said it plans to quadruple the price of its COVID-19 shot once the United States moves away from government funding to a private market for COVID-19 vaccines next year.
Moderna declined to answer questions on a new US price during a conference call to discuss third-quarter results. The company said the private market could be unpredictable and that vaccine deliveries might become seasonal, such as with flu shots.
“We anticipate a more fragmented customer base, including private payers, health plans, pharmacy chains, individual pharmacies and physician offices,” said Arpa Garay, Moderna’s chief commercial officer. “We also anticipate reduced predictability in orders.”
Along with production delays, Moderna’s third quarter was marred with manufacturing complexities due to shifting from 10-dose vials to 5-dose vials and the roll out of new bivalent vaccines that target both the original coronavirus and Omicron variants, Chief Executive Stephane Bancel said.
“We are working through a lot of those issues as we speak,” he said.
Quality control issues at contract manufacturer Catalent (CTLT.N) have led to a slow rollout of Moderna’s retooled COVID-19 boosters.
The US health regulator has been authorizing doses made at the Catalent plant on a batch-by-batch basis.
“You can tell the infancy of this company versus a Pfizer, which is scaled up and ready, and can manufacture and ship out,” said Sara LaFever, analyst at Citeline.
Moderna now expects 2022 vaccine sales of $18 billion to $19 billion compared to a prior forecast of $21 billion.
Third-quarter sales of $3.36 billion fell short of Wall Street estimates of $3.53 billion.
After initially falling to as low as $135.09 in early trading, Moderna shares recovered and were about flat at $148.79.
Reporting by Manas Mishra in Bengaluru and Michael Erman in Maplewood, New Jersey; Editing by Caroline Humer and Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.